| Ticker | BTAI |
|---|---|
| ISIN | US09075P2048 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | $28.157.569 |
| Beta | 0,3 |
| Sitio web | https://www.bioxceltherapeutics.com |
| CEO | Vimal D. Mehta |
| Fecha de IPO | 08/03/2018 |
| País | US |
| Dirección | 555 Long Wharf Drive, New Haven, CT, 06511 |
| Volumen | 635.563 |
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, subli...
BioXcel Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones